Literature DB >> 25339128

Novel SLC5A2 variants contribute to renal glucosuria in Chinese families: abnormal expression and dysfunction of variant SLC5A2.

Lei Yu1, Ping Hou, Ji-Cheng Lv, Guo-Ping Liu, Hong Zhang.   

Abstract

Familial renal glucosuria (FRG) is characterized by persistent glucosuria despite normal serum glucose and the absence of overt tubular dysfunction. Variants in solute carrier family 5 (sodium-glucose cotransporter), member 2 (SLC5A2) have been reported in FRG patients. However, the functional and expression-related consequences of such variants have been scarcely investigated. In the current study, we studied five FRG families and identified six missense mutations, including four novel variants (c.1051T>C/.(C351R), c.1400T>C/p.(V467A), c.1420G>C/p.(A474P), c.1691G>A/p.(R564Q); RNA not analyzed) and two variants that had been previously reported (c.294C>A/p.(F98L), c.736C>T/p.(P246S); RNA not analyzed). The probands were either heterozygous or compound heterozygous for SLC5A2 variants and had glucosuria of 5.9%-19.6 g/day. Human 293 cells were transfected with plasmid constructs to study the expression and function of SLC5A2 variants in vitro. Western blotting revealed that the expression levels of SLC5A2-351R-GFP, SLC5A2-467A-GFP, SLC5A2-474P-GFP, and SLC5A2-564Q-GFP were significantly decreased compared with wild-type SLC5A2-GFP (37%-55%). Confocal microscopy revealed that three variants (c.1400T>C, c.1420G>C, c.1691G>A) resulted in a loss of the punctate membrane pattern typical of wild-type SLC5A2. All variants had a significantly lower transport capacity in than the wild-type control. The current study provides a starting point to further investigate the molecular mechanism of SLC5A2 in FRG families and provides functional clues for antidiabetes drugs.
© 2014 WILEY PERIODICALS, INC.

Entities:  

Keywords:  SLC5A2; expression; familial renal glucosuria; function

Mesh:

Substances:

Year:  2014        PMID: 25339128     DOI: 10.1002/humu.22714

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  6 in total

1.  Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes.

Authors:  Shin Kawasoe; Yukiko Maruguchi; Shoko Kajiya; Hitoshi Uenomachi; Masaaki Miyata; Mariko Kawasoe; Takuro Kubozono; Mitsuru Ohishi
Journal:  BMC Pharmacol Toxicol       Date:  2017-04-10       Impact factor: 2.483

2.  Decreased expression and function of sodium-glucose co-transporter 2 from a novel C-terminal mutation: a case report.

Authors:  Lei Yu; Qiaozhi Xu; Ping Hou; Hong Zhang
Journal:  BMC Nephrol       Date:  2016-03-21       Impact factor: 2.388

3.  Novel SLC5A2 mutation contributes to familial renal glucosuria: Abnormal expression in renal tissues.

Authors:  Lei Yu; Ping Hou; Guo-Ping Liu; Hong Zhang
Journal:  Exp Ther Med       Date:  2016-05-25       Impact factor: 2.447

4.  A recurrent deletion in the SLC5A2 gene including the intron 7 branch site responsible for familial renal glucosuria.

Authors:  Xiangzhong Zhao; Li Cui; Yanhua Lang; Ting Liu; Jingru Lu; Cui Wang; Sylvie Tuffery-Giraud; Irene Bottillo; Xinsheng Wang; Leping Shao
Journal:  Sci Rep       Date:  2016-09-26       Impact factor: 4.379

5.  SLC5A2 mutations, including two novel mutations, responsible for renal glucosuria in Chinese families.

Authors:  Lei Yu; Meng Wu; Ping Hou; Hong Zhang
Journal:  BMC Nephrol       Date:  2020-02-28       Impact factor: 2.388

Review 6.  Sodium-coupled glucose transport, the SLC5 family, and therapeutically relevant inhibitors: from molecular discovery to clinical application.

Authors:  Gergely Gyimesi; Jonai Pujol-Giménez; Yoshikatsu Kanai; Matthias A Hediger
Journal:  Pflugers Arch       Date:  2020-08-07       Impact factor: 3.657

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.